TriSalus Life Sciences, Inc.

TLSISEC EDGAR

Surgical & Medical Instruments & Apparatus(DE)CIK: 1826667

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$29.4M	$18.5M	$12.4M	—	—
Cost of Goods and Services Sold	$4.1M	$2.6M	$2.3M	—	—
Gross Profit	$25.3M	$15.9M	$10.1M	—	—
Research and Development Expense	$17.7M	$29.8M	$21.4M	—	—
Operating Income (Loss)	-$36.2M	-$54.5M	-$36.4M	-$3.0M	-$108.5K
Interest Expense	—	—	$1.0K	—	—
Nonoperating Income (Expense)	—	—	—	$7.8M	-$602.9K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$24.0M	$24.6M	$22.0M	$250.5M	$252.0M
Assets, Current	$20.7M	$20.9M	$17.2M	$525.9K	$2.0M
Cash and Cash Equivalents, at Carrying Value	$8.5M	$11.8M	$9.4M	$200.9K	$1.3M
Accounts Receivable, after Allowance for Credit Loss, Current	$3.6M	$1.6M	$1.6M	—	—
Inventory, Net	$4.0M	$2.5M	$1.5M	—	—
Liabilities	$49.9M	$51.7M	$34.3M	$17.3M	$23.5M
Liabilities, Current	$10.2M	$14.7M	$32.4M	$1.6M	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$40.8M	-$50.6M	-$32.3M	-$1.7M	-$677.6K
Net Cash Provided by (Used in) Investing Activities	-$345.0K	-$1.6M	-$1.8M	$60.0K	-$250.0M
Net Cash Provided by (Used in) Financing Activities	$37.9M	$54.6M	$13.5M	$544.0K	$252.0M
Payments to Acquire Property, Plant, and Equipment	$345.0K	$588.0K	$655.0K	—	—
Payments for Repurchase of Common Stock	—	—	—	$232.4M	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)